R157
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 141
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- PROTEIN_SECRETION+0.480
- MYC_TARGETS_V1+0.340
- TGF_BETA_SIGNALING+0.310
- UV_RESPONSE_DN+0.280
- ANDROGEN_RESPONSE+0.230
- G2M_CHECKPOINT+0.160
- SPERMATOGENESIS+0.120
- E2F_TARGETS+0.090
- HEME_METABOLISM+0.080
- OXIDATIVE_PHOSPHORYLATION+0.080
Top 10 suppressed
- INTERFERON_ALPHA_RESPONSE-0.470
- INTERFERON_GAMMA_RESPONSE-0.380
- IL6_JAK_STAT3_SIGNALING-0.350
- HEDGEHOG_SIGNALING-0.340
- MYOGENESIS-0.340
- WNT_BETA_CATENIN_SIGNALING-0.340
- ALLOGRAFT_REJECTION-0.330
- APICAL_JUNCTION-0.330
- INFLAMMATORY_RESPONSE-0.320
- UV_RESPONSE_UP-0.310
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
6 twins match this tumor's tissue · 4 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SJEPD030795_D2.RNA-Seq | EPN | Posterior Fossa EPN | 0.881 |
| 2 | R146 | — | — | 0.864 |
| 3 | R169 | — | — | 0.858 |
| 4 | R127 | — | — | 0.846 |
| 5 | TCGA-BH-A204-01A-11R-A157-07 | — | B | 0.837 |
| 6 | MBCProject_2346_T1_RNA | — | B | 0.832 |
| 7 | SRR2167642 | GTEX | — | 0.824 |
| 8 | MDT-AP-3311 | Med | Medulloblastoma | 0.823 |
| 9 | TCGA-E9-A1R7-01A-11R-A14M-07 | — | B | 0.818 |
| 10 | SJEPD031786_D2.RNA-Seq | EPN | Anaplastic EPN | 0.815 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 11 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| PROTEIN_SECRETION | 0.480 | Remibrutinib | — uncovered |
| MYC_TARGETS_V1 | 0.340 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.310 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.280 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.230 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.160 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.120 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.090 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.080 | Temsirolimus | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.080 | Remibrutinib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.080 | Idelalisib | — uncovered |